Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma

Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma

Abstract Background Patients with primary refractory and relapsed neuroblastoma have a poor prognosis since safe and effective chemotherapies for these patients are currently limited. The development of new chemotherapy regimens for these patients is imperative to improve survival outcomes. Methods...

Full description

Bibliographic Details
Main Authors: Masayuki Imaya, Hideki Muramatsu, Atsushi Narita, Ayako Yamamori, Manabu Wakamatsu, Taro Yoshida, Shunsuke Miwata, Kotaro Narita, Daisuke Ichikawa, Motoharu Hamada, Eri Nishikawa, Nozomu Kawashima, Nobuhiro Nishio, Seiji Kojima, Yoshiyuki Takahashi
Format: Article
Language:English
Published: Wiley 2022-05-01
Series:Cancer Medicine
Subjects:
chemotherapy
neuroblastoma
pediatric cancer
polymorphisms
Online Access:https://doi.org/10.1002/cam4.4529

Internet

https://doi.org/10.1002/cam4.4529

Similar Items